by Michael Shanler | January 27, 2016 | Comments Off on “Accelerating R&D” Key Initiatives for Life Science Manufacturers 2016
Before each calendar year begins, we put a lot of effort into outlining areas of research and how these areas align with strategic key initiatives (KIs). The life science-related KIs for CIOs and IT leaders have been broken into several disciplined areas:
- Commercial (i.e. How to more effectively market optimal therapies and services to different customers (patients, payers, providers, etc.)
- Accelerating innovation. (i.e. How to get a new innovation – drug, service, technology or product – to market faster?)
- Supply Chain (SC) (i.e. How to intelligently manufacture high quality products with compliance?)
For R&D-related KI details, read: Accelerating R&D and New Product Innovation in Life Sciences Primer for 2016 26 January 2016 G00292958
Commercial is covered by Stephen Davies. Supply Chain quality, manufacturing and serialization, etc is covered by a host of other SC analysts. I’m the lead for the R&D KI. This year, I’m planning on breaking up the R&D-related research (research notes, surveys, executive briefing decks, workshops, presentations etc.) into the topics below. While these will mostly be contextualized for life science (pharma, biotech, medical device, CROs, etc.), a lot of this material translates reasonably well into other scientific-domain manufacturing environments (crop science, materials, cosmetics, food and beverage, etc.)
R&D Tech Trends and Cool stuff:
- Hype Cycle for Life Sciences, 2016
- Cool Vendors in Life Sciences, 2016
- Life Science Business Drivers
- Top 10 Technology Opportunities for Pharma
R&D IT productivity:
- Life Science CIO R&D IT Blueprint
- Digital Strategy Development and Best Practices
- Analytics and BI Maturity in Life Science
- Embracing “Shadow IT” as Partners, Not Adversaries
- Laboratory of the Future
- ELN/LIMS Maturity Model & Best Practices
- Laboratory Informatics Market Guide for ELN/LIMS
- Mind the Laboratory IT Service Gap
- E-Clinical Systems Evolution
- Patient Engagement and Mobile Apps in Clinical Trials
- What’s Your Reality for Real-World Evidence (RWE)?
- Identification of Medicinal Product (IDMP)…which was just published.
R&D while meeting regulatory compliance:
- Regulated vs Non Regulated ECM Tug of War
- Clinical Trial Data Transparency Readiness
- RIMS Vendors Overview
- eTMF Maturity
Of course, we’ll also contribute in special reports (IoT, 3D Printing, Digital Business, Industry Fluidity), manage tech profiles going into a bunch of related hype cycles (e.g. Healthcare, 3D Printing, PLM, Supply Chain), and stay on top of “first takes” for events and vendor M&A activities.
Yikes! Time is flying. We are already burned through 1/12 of 2016. Back to the research….
Predicts 2019: Data and Analytics Strategy
Data and analytics are the key accelerants of digitalization, transformation and “ContinuousNext” efforts. As a result, data and analytics leaders will be counted upon to affect corporate strategy and value, change management, business ethics, and execution performance.Read Free Gartner Research
Category: 3d-printing additive-manufacturing analytics clinical-development compliance ctms data-and-analytics-strategies digital-marketing eclinical edc engineering epro gartner innovation internet-of-everything internet-of-things iot it it-cost-optimization manufacturing mobile-and-endpoint-technologies nexus-of-forces nof pharma pharmaceutical product-development rd regulatory science security supply-chain technology-and-emerging-trends trends-and-predictions wearables
Tags: cloud collaboration digital-business ea innovation it-governance
Comments or opinions expressed on this blog are those of the individual contributors only, and do not necessarily represent the views of Gartner, Inc. or its management. Readers may copy and redistribute blog postings on other blogs, or otherwise for private, non-commercial or journalistic purposes, with attribution to Gartner. This content may not be used for any other purposes in any other formats or media. The content on this blog is provided on an "as-is" basis. Gartner shall not be liable for any damages whatsoever arising out of the content or use of this blog.